10-Q: Seer Inc. Reports Q2 2026 Financials Amidst Revenue Decline

Seer, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, reporting a decrease in total revenue and continued net losses, while also detailing cost-saving measures and ongoing product development.

Summary

• Seer, Inc. reported a net loss of $16.9 million for the three months ended June 30, 2026, compared to a net loss of $19.4 million in the same period last year.
• Total revenue for the quarter decreased by 23% to $3.1 million, driven by lower product and service revenue.
• Research and development expenses decreased by 32% to $8.2 million, and selling, general, and administrative expenses decreased by 5% to $10.1 million.
• The company had $209.5 million in cash, cash equivalents, and investments as of June 30, 2026, which management believes is sufficient for at least the next twelve months.
• The company is facing ongoing patent litigation related to its Proteograph Product Suite.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to continued net losses, declining revenue, and significant operating expenses, despite efforts to manage costs.

Positives

• Reduction in net loss for the quarter to $16.9 million from $19.4 million in the prior year period.
• Decrease in operating expenses, with R&D expenses down 32% and SG&A down 5%, indicating cost management efforts.
• Sufficient liquidity with $209.5 million in cash, cash equivalents, and investments, providing at least a twelve-month operating runway.
• Progress in product development with the launch of the Proteograph ONE assay and SP200 automation instrument.

Negatives

• Total revenue declined by 23% to $3.1 million for the three months ended June 30, 2026, compared to $4.1 million in the prior year.
• Net loss for the six months ended June 30, 2026, was $33.7 million, a slight improvement from $39.4 million in the prior year, but still substantial.
• Accumulated deficit stands at $499.7 million as of June 30, 2026.
• Significant ongoing operating expenses are expected to continue, with no immediate prospect of profitability.
• The company is involved in patent infringement lawsuits.

Risks

• Continued net losses and negative cash flows are expected, with no guarantee of achieving or sustaining profitability.
• The market for the Proteograph Product Suite may be smaller than estimated, or new market opportunities may not develop as quickly as anticipated.
• Failure to achieve broad scientific and market acceptance of the Proteograph Product Suite could lead to continued operating losses.
• Dependence on key personnel and the ability to attract and retain qualified employees in a competitive market.
• Reliance on a single contract manufacturer for instruments and potential supply chain disruptions.
• The company is involved in patent litigation, which could result in substantial costs and diversion of resources.
• Potential for future capital raises, which could dilute existing shareholders.
• The company's ability to use net operating losses (NOLs) may be limited by Section 382 of the Internal Revenue Code and state tax laws.

Future Outlook

The company expects to continue to incur significant expenses and operating losses in the near term while investing in growth. Management believes current cash and investments provide sufficient capital for at least twelve months of operations. Future capital requirements will depend on revenue growth, commercialization efforts, R&D, and potential acquisitions.

Management Comments

• Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth.
• Management believes that its cash and cash equivalents and investments as of June 30, 2026 provide sufficient capital resources to continue its operations for at least twelve months from the issuance date of the accompanying unaudited condensed consolidated financial statements.
• The company is focused on removing barriers to access to the Proteograph, including through the STAC service offering.

Industry Context

StockSavvy.ai notes that the life sciences and proteomics market is highly competitive and rapidly evolving. Seer's performance is being closely watched as it navigates commercialization challenges and aims to establish its proprietary technology against established players and emerging competitors.

Legal Proceedings

• Patent infringement lawsuit filed against Nanomics Biotechnology Co., Ltd. alleging infringement of five U.S. Patents.
• Complaint filed with the U.S. International Trade Commission (ITC) seeking investigation into importation and sale of Nanomics' Accused Products for infringing Asserted Patents.
• ITC formally ordered institution of an investigation into Nanomics' Accused Products.

Related Party Transactions

• Investment in PrognomiQ, Inc. through a Simple Agreement for Future Equity (SAFE) for $0.3 million on June 22, 2026.
• Previous investments in PrognomiQ's Series D Preferred Stock totaling $13.4 million.
• Related party receivables of $56,000 as of June 30, 2026.
• Related party revenue of $56,000 for the six months ended June 30, 2026, primarily from services.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to ongoing losses and market conditions.
• Employees may face uncertainty due to cost-saving measures and the company's financial performance.
• Customers may be impacted by potential supply chain disruptions or the company's ability to scale production.
• Creditors and suppliers may face risks associated with the company's ongoing losses and liquidity.

Next Steps

• Continue to build sales, marketing, service, support, and distribution infrastructure.
• Expand in-house NP manufacturing capabilities.
• Engage in research and development for other products and enhancements to the Proteograph Product Suite.
• Implement operational, financial, and management information systems.
• Obtain, maintain, expand, and protect intellectual property portfolio.
• Build infrastructure to operate and scale as a public company.
• Continue to defend against patent infringement claims.

Key Dates

Recommendation

While the company shows efforts in cost management and has sufficient liquidity for the near term, the continued revenue decline, substantial net losses, and ongoing patent litigation present significant risks. The potential for future capital raises also introduces dilution concerns. The stock is best held pending signs of revenue stabilization and a clearer path to profitability.

Keywords

proteomics, Proteograph Product Suite, life sciences, biotechnology, nanoparticle technology, R&D, financial results, SEC filing